CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Rituximab for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Details

Project Number pCODR 10180
Brand Name TBD
Generic Name Rituximab
Tumour Type Lymphoma & Leukemia
Indication Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
Funding Request Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
Review Status File-Closed Not Submitted
Clarification The submitter notified pCODR that they will not be filing the submission.
Pre Noc Submission Yes
NOC Date
Manufacturer Sandoz Canada
Sponsor Sandoz Canada
Submission Date (Target Date)
Submission Deemed Complete
Submission Type Biosimilar – New Drug
Stakeholder Input Deadline (target date based on target submission date) ‡
Final Biosimilar Summary Dossier Issued (target date)

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.